Biocept Inc. (NASDAQ:BIOC) currently has a daily average trading volume of 30.50M but it saw 16073498 shares traded on Monday. With a market cap of 123.04M USD, the company’s enterprise value now stands nearly at $BIGC. Stock’s current market price of $0.84 came falling about -7.06 while comparing to the previous closing price of $0.90. In past 52 weeks, the stock remained buoying in the range of price level as high as $1.30 and as low as $0.21. In the recent trading on the day, stock has struck highest price mark of $0.8904 while lowest mark touched by it was $0.7801.

Taking a look at 20-day trading activity of Biocept Inc. (BIOC) gives us an average price of $0.8467, while its current price level is -35.38% below from 52-week high level whereas it is 297.77% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.7500 while that of 200 days or SMA-200 reads an average of $0.4854. A closer look into the stock’s movement over the week reveals that its volatility is standing at 13.36% during that period while stretching the period over a month that decreases to 13.10%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 47.57 which implies that the stock is in neutral territory.

Biocept Inc. (BIOC)’s stock is currently under the radar of 2 analysts who are in consensus at a 12-month price target range of between $2.00 and $2.06 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $2.00 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $2.06. Average price target assigned by them is $2.03 which highlights an upside potential of 58.62% for the stock over that period. And to attain the median price target of $2.03 assigned by those analysts, stock has to add about 58.62% of value to its current levels.

Data by FactSet Research shows that 2 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 0 are advising it as an Overweight. 2 analysts suggested the investors to Buy the stock while 0 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Buy for the stock and that issued by Wall Street to investors is Moderate Buy.

The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Chardan Capital Markets which reiterated the stock as “Buy” in its note to investors issued on November 14, 2017, recommending a price target of between $2.50 and $1.50 for it. ROTH Capital issued its recommendations for the stock as it initiated the price target for the stock is $1.20.

Over the week, BIOC’s stock price is moving -24.32% down while it is 23.04% when we observe its performance for the past one month. Year-to-date it is 193.74% up and over the past year, the stock is showing a downside performance of -8.44%.

The company is expected to be releasing its next quarterly report in 11/05/2020, for which analysts forecasted an EPS of $BIGC while estimate for next year EPS is $Technology.

Currently, Biocept Inc.’s total number of outstanding shares is 131.10M. Company’s return on investment (ROI) stands at -178.70% and return on equity (ROE) at -184.60%. Stock’s beta reads 0.78. Stock has a price to book (P/B) ratio of 2.90 while price to sale or P/S ratio amounts to 20.51. Its return on asset (ROA) is -123.30% on average.

As per SEC documents, Vanguard Total Stock Market Index sought 4,181,600 of company’s common stock of worth $3.1 million as per recent closing price of the stock. Vanguard Total Stock Market Index is not the only institutional holder which restructured its stake in Biocept Inc., as Vanguard Extended Market Index Fu picked 2,206,892 shares of worth $1.64 million to bring its holdings to a total of 1.65 million shares. In the most recent quarter, Fidelity Extended Market Index Fu came cutting its stake by 0.00% in the company and now holds 0.25 million or 0.19% of the company’s stake having worth of about 0.19 million.